PDF(Pubmed)
Abstract：
Atopic dermatitis is a chronic complex inflammatory skin disorder that requires sustainable treatment methods due to the limited efficacy of conventional therapies. Sargassum serratifolium, an algal species with diverse bioactive substances, is investigated in this study for its potential benefits as a therapeutic agent for atopic dermatitis. RNA sequencing of LPS-stimulated macrophages treated with ethanolic extract of Sargassum serratifolium (ESS) revealed its ability to inhibit a broad range of inflammation-related signaling, which was proven in RAW 264.7 and HaCaT cells. In DNCB-induced BALB/c or HR-1 mice, ESS treatment improved symptoms of atopic dermatitis within the skin, along with histological improvements such as reduced epidermal thickness and infiltration of mast cells. ESS showed a tendency to improve serum IgE levels and inflammation-related cytokine changes, while also improving the mRNA expression levels of Chi3l3, Ccr1, and Fcεr1a genes in the skin. Additionally, ESS compounds (sargachromanol (SCM), sargaquinoic acid (SQA), and sargahydroquinoic acid (SHQA)) mitigated inflammatory responses in LPS-treated RAW264.7 macrophages. In summary, ESS has an anti-inflammatory effect and improves atopic dermatitis, ESS may be applied as a therapeutics for atopic dermatitis.
摘要：
特应性皮炎是一种慢性复杂的炎症性皮肤病，由于常规疗法的疗效有限，需要可持续的治疗方法。马尾藻,具有多种生物活性物质的藻类，在这项研究中研究了其作为特应性皮炎治疗剂的潜在益处。用马尾藻的乙醇提取物（ESS）处理的LPS刺激的巨噬细胞的RNA测序显示其抑制广泛的炎症相关信号的能力，这在RAW264.7和HaCaT细胞中得到了证实。在DNCB诱导的BALB/c或HR-1小鼠中，ESS治疗改善皮肤内特应性皮炎的症状，随着组织学改善，如减少表皮厚度和肥大细胞浸润。ESS显示出改善血清IgE水平和炎症相关细胞因子变化的趋势，同时也提高了皮肤中Chi3l3，Ccr1和Fcεr1a基因的mRNA表达水平。此外,ESS化合物(sargachromanol(SCM)，sargaquinoicacid(SQA),和sargahydroquinoicacid（SHQA））减轻了LPS处理的RAW264.7巨噬细胞的炎症反应。总之,ESS具有抗炎作用，改善特应性皮炎，ESS可用作特应性皮炎的治疗剂。
